ANI PHARMACEUTICALS INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Available to Common Stockholders, Basic $3.9m
($1.1m) -127.50%
$15.3m +1525.65%
$6.0m -60.91%
($22.5m) -475.99%
($42.8m) -89.79%
($49.5m) -15.72%
$17.2m +134.64%
($20.1m) -217.45%
$77.2m +483.08%
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $3.9m ($1.1m) $15.5m $6.1m ($22.5m) ($42.6m) ($47.9m) $18.8m ($18.5m) $78.3m
Depreciation, Depletion and Amortization $22.3m $27.9m $33.7m $44.6m $44.6m $47.3m $59.7m $59.8m $67.7m $91.4m $85.8m
Depreciation $900k $1.2m $2.1m $4.4m $4.8m $5.5m $7.4m $7.5m $7.4m $8.9m $85.8m
Amortization of Debt Issuance Costs $844k $845k $1.5m $1.4m $720k $914k $2.4m $2.4m $0
Amortization of Debt Issuance Costs and Discounts $7.3m $7.7m $8.5m $7.0m $1.9m $2.5m $4.0m $3.9m $642k $1.4m
Amortization of Intangible Assets $21.4m $26.7m $31.7m $40.2m $39.9m $41.8m $49.5m $52.3m $60.3m $82.5m
Deferred Income Tax Expense (Benefit) ($9.0m) $3.5m ($5.4m) ($7.3m) ($13.0m) ($16.9m) ($15.2m) ($11.6m) ($23.0m) $11.8m $18.7m
Share-based Payment Arrangement, Noncash Expense $6.1m $6.1m $6.8m $9.2m $12.9m $10.5m $14.6m $20.7m $29.3m $37.9m $41.1m
Share-based Payment Arrangement, Expense $6.1m $6.0m $6.7m $9.1m $12.8m $10.4m $14.3m $41.1m
Goodwill, Impairment Loss $0 $0 $0 $0 $0 $0 $0 $0 $767k
Impairment of Intangible Assets, Finite-lived $6.7m $903k $0 $75k $446k $2.4m $112k $0 $3.6m $800k
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $4.0m $0
Other Nonoperating Income (Expense) ($74k) $55k ($550k) ($228k) ($494k) ($4.3m) $670k ($159k) ($4.0m) $1.9m
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable $24.0m $12.9m $4.7m $7.3m $23.7m $5.5m $36.9m ($3.4m) $21.1m $58.5m ($48.4m)
Increase (Decrease) in Inventories $1.9m ($5.4m) $379k $7.7m $2.8m ($3.2m) $23.6m $5.8m $21.3m $6.0m ($4.6m)
Increase (Decrease) in Accounts Payable $1.1m $3k $3.5m $5.0m ($2.3m) $10.2m $5.0m $7.6m $479k $15.2m $10.8m
Gain (Loss) on Disposition of Other Assets $0 $0 $5.3m ($382k)
Net Cash Provided by (Used in) Operating Activities $27.5m
$39.4m +43.49%
$67.1m +70.16%
$45.6m -31.97%
$15.3m -66.54%
$3.3m -78.24%
($31.2m) -1039.28%
$119.0m +481.24%
$64.0m -46.19%
$185.2m +189.34%
$189.5m +2.29%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $4.6m $10.4m $5.7m $6.6m $6.1m $2.6m $8.9m $8.9m $16.2m $13.8m ($21.9m)
Gain (Loss) on Disposition of Property Plant Equipment ($4.6m) ($10.4m) ($5.7m) ($6.6m) ($6.1m) ($2.6m) ($8.9m) ($8.9m) $5.3m ($13.8m) $382k
Payments to Acquire Businesses, Net of Cash Acquired $16.5m $0 $0 $84.5m $33k $0 $0
Net Cash Provided by (Used in) Investing Activities ($154.1m) ($108.0m) ($27.4m) ($27.5m) ($68.3m) ($105.5m) ($15.7m) ($18.5m) ($404.7m) ($34.3m) ($21.9m)
Cash flows from financing activities:
Gain (Loss) on Extinguishment of Debt $0 $0 ($1.5m) $0 $0 ($7.5m) $0
Proceeds from Issuance of Long-term Debt $75.0m $0 $0 $0
Payments for Repurchase of Common Stock $2.5m $0 $0 $890k $2.0m $5.0m $11.0m $12.2m
Proceeds from Issuance of Common Stock $75.0m $80.6m $0 $0 $0
Dividends paid $190k $1.6m $1.6m $1.6m $1.2m ($344k)
Other Interest and Dividend Income $6.3m $4.9m
Net Cash Provided by (Used in) Financing Activities ($729k)
$72.4m +10025.51%
($27.8m) -138.44%
$1.2m +104.49%
($1.4m) -215.12%
$194.6m +13622.93%
($5.1m) -102.63%
$67.4m +1415.63%
$264.9m +292.87%
($9.9m) -103.75%
($24.6m) -146.92%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $0 $167.9m ($76.2m) $140.7m $360.8m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.1m $48.0m $67.4m $12.9m $105.3m $53.2m $221.1m $144.9m $285.6m $360.8m
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $0 $0 ($470k) ($233k) ($554k)
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $1.6m $353k $3.0m $5.7m $618k $2.1m $1.5m $9.0m $6.5m $13.6m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $4.1m $3.8m $6.3m $6.1m $6.9m $9.7m $21.5m $31.4m $24.4m $26.9m
Income Taxes Paid, Net $9.5m $17.8m $6.4m $10.0m $5.0m $10.4m $288k $1.2m $19.1m $17.7m
Additional Financial Items
Equity Securities, FV-NI, Unrealized Gain (Loss) $0 $0 $6.3m $2.8m
Gain (Loss) on Disposition of Assets $0 $0 ($5.3m) ($382k)
Gain (Loss) on Disposition of Intangible Assets $1.8m $750k $0 $0 $382k
Gain (Loss) Related to Litigation Settlement ($8.8m) $0
Goodwill $1.8m $1.8m $3.6m $3.6m $3.6m $27.9m $28.2m $28.2m $60.0m $62.5m $767k
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent $3.9m ($1.1m) $15.5m $6.1m
Income Tax Expense (Benefit) $4.7m $17.4m $4.6m ($2.9m) ($3.4m) ($13.5m) ($14.8m) $1.1m ($3.7m) $17.5m